Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vivek Tank

Vascular Neurology Denison, TX Medical Doctor

NPI 1508063900 CMS profile 491696

5012 S US Highway 75 Ste 230, Denison, TX 75020

Open in the dashboard

General payments

$6,653

144 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vivek Tank of Denison, TX is reported in the CMS Open Payments database as having received $6,653 across 144 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Vascular Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $494 13
2024 General $490 12
2023 General $661 18
2022 General $731 18
2021 General $1,914 42
2020 General $1,032 23
2019 General $1,331 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vivek Tank
  • Vascular Neurology median
  • Middle half of Vascular Neurology
  • National median

In program year 2025, general payments to Vivek Tank were reported at $494. Among 416 Vascular Neurology profiles paid that year, the median was $360 and the middle half received between $91 and $1,472.

Show as a table
Year Vivek Tank Vascular Neurology median Middle half National median
2019 $1,331 $263 $102–$1,640 $163
2020 $1,032 $153 $45–$1,000 $114
2021 $1,914 $261 $100–$1,355 $132
2022 $731 $242 $87–$1,273 $149
2023 $661 $322 $97–$1,266 $160
2024 $490 $247 $70–$1,053 $164
2025 $494 $360 $91–$1,472 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $1,951 43 payments
  2. Medtronic, Inc. $678 14 payments
  3. Penumbra, Inc. $623 11 payments
  4. Janssen Pharmaceuticals, Inc $522 11 payments
  5. Relypsa, Inc. $492 5 payments
  6. Terumo Medical Corporation $409 1 payment
  7. Balt USA, LLC $296 2 payments
  8. Abbott Laboratories $281 16 payments
  9. Pfizer Inc. $247 4 payments
  10. Imperative Care, INc $179 2 payments
  11. Other $976 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,769 139 payments
  2. Travel and Lodging $801 3 payments
  3. Gift $60 1 payment
  4. Entertainment $23 1 payment
Products named General payments · program years 2019–2025
  1. SURPASS EVOLVE $940 18 payments
  2. TARGET $882 20 payments
  3. XARELTO $522 11 payments
  4. Rist-5F $501 3 payments
  5. Glidesheath $409 1 payment
  6. TR Band $409 1 payment
  7. GlideWire $409 1 payment
  8. Navicross $409 1 payment
  9. TREVO $408 5 payments
  10. ATLAS $403 5 payments
  11. Other $4,416 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

67

Median for Neurology: 833

Drug cost

$730

Median for Neurology: $202,670

Branded share of claims

100%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 67 $730

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$57,590

Medicare's payments for the services billed

Medicare patients

143

Average age 77

Services billed

493

77 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 57%
Diabetes 45%
COPD 40%
Atrial fibrillation 38%
Heart failure 33%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Neurology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record